Dentsply Sirona (XRAY) Q1 call highlights restructuring, AI diagnostics and distribution push

Dentsply Sirona (XRAY) reported first-quarter revenue that was flat year over year but ahead of Wall Street expectations, as management said restructuring efforts and commercial investments supported early customer engagement gains. CEO Daniel T. Scavilla said the dental products maker remains “in transition,” with most expected benefits from operational changes still ahead. Management cited ongoing external market pressure and segment-specific weakness, while pointing to new distribution partnerships and investment in AI-enabled diagnostic products as areas to watch. Key investor focus areas after the May 15, 2026, earnings-call review include the timing of restructuring savings, potential margin improvement, adoption of digital products, and whether expanded distribution can drive U.S. and international market share. Dentsply Sirona shares recently traded at $11.00, down from $11.37 before the earnings update.